Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.54 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14083299 | 0.91 | RXFP1 (0.61) | RXFP1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL14083089 | 0.90 | MEN1 (0.51) | RAB9ANPC1SMN1; SMN2ALDH1A1PKM | |
| SCHEMBL14083640 | 0.90 | RAB9A (0.55) | RXFP1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL14083115 | 0.88 | MAPT (0.54) | RXFP1TP53KMT2ATSHRMAPT | |
| SCHEMBL14084086 | 0.88 | TRPV1 (0.57) | RXFP1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL14083375 | 0.88 | NPC1 (0.57) | RXFP1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL14083114 | 0.86 | KCNQ3 (0.54) | RAB9ANPC1SMN1; SMN2ALDH1A1PKM | |
| SCHEMBL14083098 | 0.86 | SMN1; SMN2 (0.59) | RAB9ANPC1SMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL14083096 | 0.85 | KCNQ3 (0.56) | RAB9AKMT2AGRM4 | |
| SCHEMBL14083104 | 0.85 | TRPV1 (0.51) | TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | RXFP1 1053/4885RAB9A 1914/4885NPC1 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.